Exact Mass: 559.130139
Exact Mass Matches: 559.130139
Found 35 metabolites which its exact mass value is equals to given mass value 559.130139,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
dTDP-D-desosamine
dTDP-beta-L-evernosamine
dTDP-4-ethylamino-3-O-methyl-2,4-dideoxy-L-threo-pentopyranose
Gadoteridol
C17H29GdN4O7 (559.1277253999999)
Gadoteridol provides contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. Gadoteridol can also be used for whole body contrast enhanced MRI including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies. n MRI, visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in T2. When placed in a magnetic field, gadoteridol shortens the T1 relaxation time in tissues where it accumulates. Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadoteridol in lesions such as neoplasms, abscesses, and subacute infarcts. V - Various > V08 - Contrast media > V08C - Magnetic resonance imaging contrast media > V08CA - Paramagnetic contrast media
Acetic acid, 2-(4-((5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazol-1-yl)sulfonyl)phenoxy)-
convolutamide A|N-Tetradecanoyl-Deacylconvolutamide
C24H35Br2NO4 (559.0932670000001)
Gadoteridol
C17H29GdN4O7 (559.1277253999999)
V - Various > V08 - Contrast media > V08C - Magnetic resonance imaging contrast media > V08CA - Paramagnetic contrast media
4-(4-METHYLTHIOPHEN-2-YL)-N-(4-(MORPHOLINOMETHYL)PHENYL)-7-TOSYL-7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINE
GADOTERIC ACID
V - Various > V08 - Contrast media > V08C - Magnetic resonance imaging contrast media > V08CA - Paramagnetic contrast media D064449 - Sequestering Agents > D002614 - Chelating Agents
2-(dimethylamino)-2-biphenylyl-palladium(ii) chloride dinorbornylphosphine complex
C28H37ClNPPd (559.1386752000001)
7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine (-)-mandelate
4-Methylumbelliferyl 3,4,6-tri-O-acetyl-2-deoxy-2-trifluoroacetamido-b-D-glucopyranoside
[6-(Diethylamino)-9-(2,4-disulfophenyl)xanthen-3-ylidene]-diethylazanium
Gadolinium-HP-Do 3A
C17H29GdN4O7 (559.1277253999999)
V - Various > V08 - Contrast media > V08C - Magnetic resonance imaging contrast media > V08CA - Paramagnetic contrast media
2-[(2R,4aS,12aS)-5-methyl-6-oxo-8-(2,2,2-trifluoroethylsulfonylamino)-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(3-fluorophenyl)acetamide
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-{[1-(6,7-dimethoxy-2H-1,3-benzodioxol-5-yl)-2-hydroxy-3-oxopropyl]sulfanyl}ethyl}-C-hydroxycarbonimidoyl)butanoic acid
C22H29N3O12S (559.1471874000001)
(3s)-3-(3,4-dibromo-5-hydroxyphenyl)-3-hydroxy-1-tetradecanoylpyrrolidin-2-one
C24H35Br2NO4 (559.0932670000001)
12,13,25,26-tetrahydroxy-8,9,9-trimethyl-7-oxa-27,28-dithia-3,16,18-triazaoctacyclo[12.12.2.0¹,¹⁶.0³,¹⁴.0⁴,¹².0⁶,¹⁰.0¹⁷,²⁵.0¹⁹,²⁴]octacosa-6(10),19,21,23-tetraene-2,11,15-trione
(1s,8r,13s,14s,17s,26s)-12,13,25,26-tetrahydroxy-8,9,9-trimethyl-7-oxa-27,28-dithia-3,16,18-triazaoctacyclo[12.12.2.0¹,¹⁶.0³,¹⁴.0⁴,¹².0⁶,¹⁰.0¹⁷,²⁵.0¹⁹,²⁴]octacosa-6(10),19,21,23-tetraene-2,11,15-trione
3-(3,4-dibromo-5-hydroxyphenyl)-3-hydroxy-1-tetradecanoylpyrrolidin-2-one
C24H35Br2NO4 (559.0932670000001)